Hutchison China Meditech Ltd (HCM)

 

Latest News

Chi-Med to host R&D Briefings

RNS Number: 0625A Hutchison China Meditech Limited 21 March 2017 Press Release Chi-Med to host R&D Briefings on March 29 & 30, 2017 London: Tuesday, March 21, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that it will host Research & Development ("R&D") briefings in London and New York to provide an o...

Director Deals - Hutchison China Meditech Ltd (HCM)

Paul Carter, Non Executive Director, bought 2,800 shares in the company on the 15th March 2017 at a price of 2637.00p. Th...

Directors' Share Dealing

RNS Number: 9126Z Hutchison China Meditech Limited 20 March 2017 Directors' Share Dealing London: Monday, March 20 , 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notifications that:- 1. Mr Paul Carter, Independent Non-executive Director, purchased a total of 2,800 ordinary shares of US$1.00 each in the capital of Ch...

Grant of Awards under Long Term Incentive Plan

RNS Number: 6898Z Hutchison China Meditech Limited 16 March 2017 Press release Grant of Awards under Long Term Incentive Plan London: Thursday , March 1 6 , 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces that on March 15, 2017 , it granted conditional awards ("LTIP Awards") under the Long Term Incentive Plan ("L...

All News

DateHeadlineSource
21-03-17Chi-Med to host R&D BriefingsRNS
20-03-17Director Deals - Hutchison China Meditech Ltd (HCM)StockMarketWire
20-03-17Directors' Share DealingRNS
16-03-17Grant of Awards under Long Term Incentive PlanRNS
13-03-17Hutchison China MediTech shares tipped to hit record highInteractive Investor
13-03-17Higher commodity prices boost FTSE as May considers triggering Article 50StockMarketWire
13-03-17Record revenues and net income at Chi-Med StockMarketWire
13-03-17Publication of Form 20-FRNS
13-03-17Final ResultsRNS
10-03-17Chi-Med presents pre-clinical data at ENETSStockMarketWire
10-03-17Sulfatinib Phase Ib/II Results Presented at ENETSRNS
10-03-17Sulfatinib Phase Ib/II Results Presented at ENETSRNS
03-03-17Chi-Med reveals positive results from cancer drug trial StockMarketWire
03-03-17Positive Fruquintinib Pivotal Phase III ResultsRNS
28-02-17Board changes at HCMStockMarketWire
28-02-17Change of DirectorsRNS
20-02-17Chi-Med starts Savolitinib PSC trial in ChinaStockMarketWire
20-02-17Start of Phase II Savolitinib PSC trial in ChinaRNS
20-02-17Start of Phase II Savolitinib PSC trial in ChinaRNS
14-02-17Chi-Med and AZ to present savolitinib results at symposiumStockMarketWire
14-02-17Initiates Phase I of Novel FGFR Inhibitor HMPL-453RNS
14-02-17Savolitinib PRCC Results Presentation at ASCO GURNS
06-02-17Chi-Med to Announce 2016 Final ResultsRNS
01-02-17Change of DirectorsRNS
20-01-17Why resurgent AIM could keep rising Interactive Investor
16-01-17Change of DirectorsRNS
16-01-17Change of DirectorsRNS
16-01-17Chi-Med launches cancer studies in China StockMarketWire
16-01-17Fruquintinib Phase I/II Clinical Data at ASCO GIRNS
16-01-17Sulfatinib Phase II Study in 2nd Line BTC in ChinaRNS
16-01-17Fruquintinib Combination Study in 1st-Line NSCLCRNS
10-01-17 Chi-Med initiates HMPL-523 clinical trialsStockMarketWire
10-01-17Chi-Med Initiates HMPL-523 Clinical TrialsRNS
30-12-16Total Voting RightsRNS
29-12-16Blocklisting Six Monthly ReturnRNS
20-12-16Director's Share DealingRNS
14-12-16Director's Share DealingRNS
06-12-16Chi-Med presents pre-clinical data at ASHStockMarketWire
06-12-16HMPL-523 Pre-clinical Data Presented at ASHRNS
30-11-16Exercise of Share OptionsRNS

RSS feeds

  • Editorial news feed for LSE:HCM Editorial
  • Regulatory news feed for LSE:HCM Regulatory